Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Wednesday

Syndax Pharmaceuticals (NASDAQ:SNDX) is set to release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.96) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same quarter last year, the business earned ($0.62) earnings per share. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syndax Pharmaceuticals Trading Up 1.0 %

Syndax Pharmaceuticals stock traded up $0.23 during midday trading on Monday, reaching $22.28. 19,928 shares of the company were exchanged, compared to its average volume of 1,117,484. The firm’s 50-day simple moving average is $22.56 and its 200-day simple moving average is $19.99. Syndax Pharmaceuticals has a 1 year low of $11.22 and a 1 year high of $25.34.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. Scotiabank downgraded Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and lowered their price objective for the company from $36.00 to $23.00 in a research report on Wednesday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.42.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).